Anixa Biosciences IncANIX
Price (close)
$2.78
Market cap
$96.6M
P/E
—
Revenue (TTM)
—
Net income
-$10.4M
Dividend yield
—
1-year total return
-17.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Anixa Biosciences Inc does.
Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.
Our therapeutics program consists of the development of liraltagene autoleucel (“lira-cel”), a chimeric endocrine receptor-T
cell therapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $512,000 | — | $210,000 | $210,000 | — |
| Net income | -$10.0M | -$13.0M | -$13.6M | -$9.8M | -$12.6M | -$10.9M |
| Free cash flow | -$6.2M | — | — | — | — | — |
More on ANIX.
- Anixa Biosciences Inc summary
- Anixa Biosciences Inc financial statements
- Anixa Biosciences Inc key metrics
- Anixa Biosciences Inc health scores and style box
- Anixa Biosciences Inc earnings
- Anixa Biosciences Inc dividends
- Anixa Biosciences Inc valuation
- Anixa Biosciences Inc ownership and insiders
- Anixa Biosciences Inc peers
Figures from Anixa Biosciences Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.